{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-033411","form_type":"8-K","ticker":null,"cik":"0001029125","company_name":"Panbela Therapeutics, Inc.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.943320+00:00","generated_at":"2026-06-07T19:08:11.618310+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Panbela receives Nasdaq delisting notice for bid price non-compliance; appeals hearing planned","bullets":["Nasdaq notified Panbela on Nov 28, 2023 of bid price <$1 for 30 consecutive days; no grace period due to cumulative reverse splits >250:1.","Trading suspension scheduled Dec 7, 2023, but company will appeal to Nasdaq Hearings Panel by Dec 5 to stay delisting.","Also not compliant with minimum stockholders' equity of $2.5M; reported deficit of $2.483M as of Sep 30, 2023.","Company intends to request hearing and may seek stockholder approval for another reverse split to regain compliance.","No assurance that Panel will grant continued listing; stock remains listed pending hearing decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-033411","json":"https://secwatch.observer/filing/0001437749-23-033411.json","markdown":"https://secwatch.observer/filing/0001437749-23-033411.md","text":"https://secwatch.observer/filing/0001437749-23-033411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/pbla20231201_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:08:11.618310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68323a47aa60476c0b89fb526b346f3b6b246e83","claim":"Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).","evidence_excerpt":"ion letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Staff also noted that the Company effected a 1:40 reverse stock split on January 13, 2023, and a 1:30 reverse stock split on June 1, 2023. Because the Company effected one or more reverse stock splits over the prior two-year period with a cumulat","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)(iv)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"7555d2f0bcc92d14e8286c9bb23c37e3ffc5fcd1","claim":"Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b), 5810(c)(2)(A)).","evidence_excerpt":"the Nasdaq Hearings Panel (the “Panel”) by 4:00 p.m. Eastern Time on December 5, 2023. In addition, the Letter provided notification to the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b) (the “Minimum Stockholders’ Equity Requirement”) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. The Company reported a stockholders’ deficit of $2,483,000 for the period ended September 30, 2023, and as of that date, the Compan","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1029125/000143774923033411/0001437749-23-033411-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b), 5810(c)(2)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}